STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.

Paul Hastings Advises Bank of America and Morgan Stanley on $4.5 Billion Committed Bridge Financing for Vertex’s $10 Billion Acquisition of Crinetics

Conflicts of interest threaten integrity of GLP-1 therapy guidance, experts warn

This article discusses the risks of conflicts of interest in clinical guidance for GLP-1 receptor agonists (like Ozempic, Wegovy) used for o

Ipsen acquires Kartos Therapeutics in $1.75 billion deal

GSK acquires cancer drug developer Nuvalent in $10.6 billion deal

GSK has announced a $10.6 billion acquisition of Nuvalent, a biotech company developing small-molecule kinase inhibitors for treatment-resis

Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases